Therapeutic Use of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): A review of recent experience

References

• Praloran V. Structure, biosynthesis and biological roles of monocyte-macrophage colony stimulating factor (CSF-1 or M-CSF). Nouv Rev Fr Hematol 1991; 33: 323–33
   PubMedGoogle Scholar
• Demetri G D, Griffin J D. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791–808
   PubMed Web of Science ®Google Scholar
• Tabbara I A, Robinson B E. Hematopoietic growth factors. Anticancer Res 1991; 11: 81–90
   PubMed Web of Science ®Google Scholar
• Kanz L, Lindeman A, Oster W, Herrmann F, Mertelsmann R. Hemopoietins in clinical oncology. Am J Clin Oncol 1991; 14: S27–S33
   Web of Science ®Google Scholar
• Rapoport A P, Abboud C N, DiPersio J F. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation. Blood Rev 1992; 6: 43–57
   PubMed Web of Science ®Google Scholar
• Burgess A W, Camakaris J, Metcalf D. Purification and properties of colony stimulating factor from mouse lung conditioned medium. J Biol Chem 1977; 252: 1998–2003
   PubMed Web of Science ®Google Scholar
• Huebner K, Isobe M, Crow C M, Golde D W, Kaufman S E, Gasson J C. The human gene encoding GM-CSF is at 5q21-q32, the chromosome region deleted in the 5q-anomaly. Science 1985; 230: 1282–5
   PubMed Web of Science ®Google Scholar
• Schrader J W, Ziltener H J, Leslie K B. Structural homologies among the hemopoietins. Proc Natl Acad Sci USA 1986; 83: 2458–62
   PubMed Web of Science ®Google Scholar
• Sieff C A, Emerson S G, Donahue R E, et al. Human recombi-nant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin. Science 1985; 230: 1171–3
   PubMed Web of Science ®Google Scholar
• Metcalf D, Begley C G, Johnson G R, et al. Biologic properties in vitro of a recombinant granulocyte-macrophage colony-stimulating factor. Blood 1986; 67: 37–45
   PubMed Web of Science ®Google Scholar
• Clark S C. Biological activities of human granulocyte-macrophage colony-stimulating factor. Int J Cell Cloning 1988; 6: 365–77
   PubMedGoogle Scholar
• Stahl C P, Winton E F, Munroe M C, et al. Recombinant human granulocyte-macrophage colony-stimulating factor promotes megacaryocyte maturation in nonhuman primates. Exp Hematol 1991; 19: 810–6
   PubMed Web of Science ®Google Scholar
• McNiece I K, Stewart F M, Deacon D M, Quesenberry P J. Synergistic interactions between hematopoietic growth factors as detected by in vitro mouse bone marrow colony formation. Exp Hematol 1988; 16: 383–8
   PubMed Web of Science ®Google Scholar
• Donahue R E, Wang F A, Stone D K, et al. Stimulation of hematopoiesis in primates by continuous infusion of recombinant GM-CSF. Nature 1986; 32: 872–5
   Google Scholar
• Welte K, Bonilla M A, Gillio A P, et al. Recombinant human granulocyte colony-stimulating factor: effects on hemdtopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987; 165: 941–8
   PubMed Web of Science ®Google Scholar
• Sutherland H J, Eaves C J, Lansdorp P M, Thacker J D, Hogge D E. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 1991; 78: 666–72
   PubMed Web of Science ®Google Scholar
• Paquette R L, Zhou J Y, Yang Y C, Clark S C, Koeffler H P. Recombinant gibbon interleukin-3 acts synergistically with recombinant human G-CSF and GM-CSF in vitro. Blood 1988; 71: 1596–600
   PubMed Web of Science ®Google Scholar
• Saeland S, Caux C, Favre C, et al. Combined and sequential effects of human IL-3 and GM-CSF on the proliferation of CD34 + hematopoietic cells from cord blood. Blood 1989; 73: 1195–201
   PubMed Web of Science ®Google Scholar
• Pebusque M J, Fay C, Lafage M, et al. Recombinant human IL-3 and G-CSF act synergistically in stimulating the growth of acute myeloid leukemia cells. Leukemia 1989; 3: 200–5
   PubMed Web of Science ®Google Scholar
• Curtis B M, Williams D E, Broxmeyer H E, et al. Enhanced hernatopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein. Proc Natl Acad Sci USA 1991; 88: 5809–13
   PubMed Web of Science ®Google Scholar
• Kharazmi A, Nielsen H, Hovgaard D, Borregaard N, Nissen N I. Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma. Eur J Clin Invest 1991; 21: 219–24
   PubMed Web of Science ®Google Scholar
• Yonk K, Addison I E, Johnson B, Webster A D, Lynch D C. Role of leucocyte integrins in phagocyte responses to granulo-cyte-macrophage colony-stimulating factor (GM-CSF): in vitro and in vivo studies on leucocyte adhesion deficiency neutrophils. Br J Hematol 1991; 77: 150–7
   PubMed Web of Science ®Google Scholar
• Volk H D, Thieme M, Heym S, et al. Alterations in function and phenotype of monocytes from patients with septic disease—Predictive value and new therapeutic strategies. Behring Inst Mitt 1991; 88: 208–15
   Google Scholar
• Biesma B, Willemse P H, Vellenga E, Limburg P C, Aalders J G, deVries E G. The hematopoietic growth factor GM-CSF in chemotherapy for ovarian carcinoma. Ned Tijdschr Ge-neeskd 1991; 135: 420–4
   PubMedGoogle Scholar
• Hoekman K, Wagstaff J, Boven E, van Groeningen C J, Vermoken J B, Pinedo H M. The hematopoietic growth factor GM-CSF in chemotherapy for advanced breast carcinoma. Ned Tijdschr Geneeskd 1991; 135: 415–9
   PubMedGoogle Scholar
• Jost L M, Pichert G, Stahel R A. Placebo controlled phase 1/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy. Ann Oncol 1990; 6: 439–42
   Google Scholar
• Antman K S, Griffin J D, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319: 593–8
   PubMed Web of Science ®Google Scholar
• Biesma B, deVries E G, Willemse P H, et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 1991; 26: 932–6
   Web of Science ®Google Scholar
• Anderson H, Gurney H, Thatcher N, Swindell R, Scarffe J H, Weiner J. Recombinant human GM-CSF in small cell lung cancer: a phase I/II study. Recent Results Cancer Res 1991; 121: 155–61
   PubMedGoogle Scholar
• Ardizzoni A, Sertoli M R, Corcione A, et al. Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomized pilot study. Eur J Cancer 1991; 26: 937–41
   Web of Science ®Google Scholar
• Thomassen M J, Ahmad M, Barna B P, et al. Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy. Cancer Res 1991; 51: 857–62
   PubMed Web of Science ®Google Scholar
• Berdel W E, Danhauser-Riedl S, Steinhauser G, Rastetter J. Stimulation of clonal growth of human colorectal cells by IL-3 and GM-CSF: modulation of 5-FU cytotoxicity by GM-CSF. Onkologie 1990; 13: 437–43
   PubMedGoogle Scholar
• Gratwohl A, Dazzi H, Tiechelli A, et al. Emergency therapy with granulocyte-macrophage colony-stirdating factor (GM-CSF). Schweiz Med Wochenschr 1991; 121: 413–7
   PubMedGoogle Scholar
• Kim I S, Gratwohl A, Staebler C, et al. Accidental overdose of multiple chemotherapeutic agents. Korean J Intern Med 1989; 4: 171–3
   PubMedGoogle Scholar
• Fielder W, Goetz G, Weh H J, Hossfeld D K. GM-CSF in busulfan overdosage. Eur J Hematol 1990; 45: 183–4
   PubMed Web of Science ®Google Scholar
• Butturini A, de Souza P C, Gale R P, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor in the Brazil radiation accident. Lancet 1988; 2: 471–4
   PubMed Web of Science ®Google Scholar
• Ho A D, Haas R, Korbling M, Dietz M, Hunstein W. Utilization of recombinant human GM-CSF to enhance peripheral progenitor cell yield for autologous transplantation. Bone Marrow Transplant 1991; 7: 13–7
   PubMed Web of Science ®Google Scholar
• Tavassoli M, Konno M, Shiota Y, Omoto E, Minguell J J, Zanjani E D. Enhancement of the grafting efficiency of transplanted marrow cells by preincubation with interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 1599–606
   PubMed Web of Science ®Google Scholar
• Brandt S J, Peters W P, Atwater S K, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869–76
   PubMed Web of Science ®Google Scholar
• Visani G, Tosi P, Gamberi B, et al. Accelerated hemopoietic recovery after chemotherapy and autologous bone marrow transplantation in hematological malignancies using recombinant GM-CSF: preliminary results obtained in 14 cases. Haematologica 1990; 75: 551–4
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Singer J W. The use of recornbinant human granulocyte-macrophage colony stimulating factor in autologous bone marrow transplantation. Am J Clin Oncol 1991; 14S: S15–8
   Google Scholar
• Brandwein J M, Nayar R, Baker M A, et al. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation. Exp Hematol 1991; 19: 191–5
   PubMed Web of Science ®Google Scholar
• Heslop H E, Duncombe A S, Reittie J E, et al. Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol 1991; 77: 237–44
   PubMed Web of Science ®Google Scholar
• Atkinson K, Matias C, Guiffre A, et al. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin 1 (IL-I), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991; 77: 1376–82
   PubMed Web of Science ®Google Scholar
• Powles R, Smith C, Milan S, et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417–20
   PubMed Web of Science ®Google Scholar
• Cannistra S A. Growth regulation of malignant clonogenic cells in acute myeloid leukemia. Curr Opin Oncol 1991; 3: 4–12
   PubMedGoogle Scholar
• Koenigsmann M, Hiddemann W, Buchner T. Reversible leukaemic regrowth under GM-CSF treatment after chemotherapy for AML. Leuk Res 1991; 15: 37–41
   PubMed Web of Science ®Google Scholar
• Ben-Ishay Z, Pridull G, Sharon S. Improved prognosis in mice with advanced myeloid leukemia following adrninistration of GM-CSF. Leuk Res 1991; 15: 321–5
   PubMed Web of Science ®Google Scholar
• Tolomeo M, Luparello M, Caravello E, et al. Potentiation of the antiblastic activity of mafosfamide by GM-CSF and interleukin-3: a possible use in the treatment of acute myeloblastic leukemia. Ann Ital Med Int 1990; 5: 341–7
   PubMedGoogle Scholar
• Bettelheim P, Valent P, Andreeff M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction therapy in de novo acute myeloid leukemia. Blood 1991; 77: 700–11
   PubMed Web of Science ®Google Scholar
• Hollander A A, Kluin-Nelemans H C, Haak H R, Willemze R, Fibbe W E. Correction of neutropenia associated with chronic lymphocytic leukaemia following treatment with granulocyte macrophage colony-stimulating factor. Ann Hematol 1991; 62: 32–4
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Talpaz M, Gomez J A, et al. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low over high-dose administration in selected patients. Br J Hematol 1991; 78: 352–8
   PubMed Web of Science ®Google Scholar
• Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990; 75: 1056–63
   PubMed Web of Science ®Google Scholar
• Hammond W P, Prue T H, Souza L M, Dale D C. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 1989; 320: 1306–11
   PubMed Web of Science ®Google Scholar
• Jakubowski A A, Souza L, Kelly F, et al. Effects of human granulocyte colony-stimulating factor in a patient with idio-pathic neutropenia. N Engl J Med 1989; 320: 38–42
   PubMed Web of Science ®Google Scholar
• Freund M RF, Luft S, Schober C, et al. Differential effects of GM-CSF and G-CSF in cyclic neutropenia. Lancet 1990; 336: 313
   PubMed Web of Science ®Google Scholar
• Wodzinski M A, Hampton K K, Reilly J T. Differential effects of G-CSF and GM-CSF in acquired chronic neutropenia. Br J Hematol 1991; 77: 249–50
   PubMed Web of Science ®Google Scholar
• Hazenberg B PC, Van Leuwen M A, Van Rijswik M H, Stern A C, Vellenga E. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989; 74: 2769–76
   PubMed Web of Science ®Google Scholar
• Geetha J, Neustadt D H, Hamm J, Kellihan M, Hadley T. GM-CSF in the treatment of Felty syndrome. Am J Hematol 1991; 37: 55–6
   PubMed Web of Science ®Google Scholar
• Lubbe A S, Schwella N, Riess H, Huhn D. Improvement of pneumonia and arthritis in Felty's syndrome by treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF). Blut 1990; 61: 379–80
   PubMedGoogle Scholar
• Nand S, Bayer R, Prinz R A, Felten W, Godwin J E. Granulocyte-macrophage colony-stimulating factor for the treatment of drug induced agranulocytosis. Am J Hematol 1991; 37: 267–9
   PubMed Web of Science ®Google Scholar
• Palmblad J, Johnson B, Kanerud L. Treatment of drug-induced agranulocytosis with recombinant GM-CSF. J Intern Med 1990; 228: 537–9
   PubMed Web of Science ®Google Scholar
• Champlin R E, Nimer S D, Ireland P, Oette D H, Golde D W. Treatment of refractory aplastic anemia with recombinant granulocyte-macrophage colony-stimulating factor. Blood 1989; 73: 694–9
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Buescher S, Browmeyer H E, et al. Stimulation of myelopoiesis in patients with aplastic anemia with recombinant granulocyte-macrophage colony-stimulating factor. N Engl J Med 1988; 319: 1628–34
   PubMed Web of Science ®Google Scholar
• Nissen C, Tichelli A, Gratwohl A, et al. Failure of recombinant human granulocyte-macrophage colony-stimulating factor therapy in aplastic anemia with severe neutropenia. Blood 1988; 72: 2045–7
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Piaggio G, Figari O, et al. Response of CFU-GM to increasing doses of rhGM-CSF in patients with aplastic anemia. Exp Hematol 1991; 19: 829–32
   PubMed Web of Science ®Google Scholar
• Herrmann F, Lindemann A, Ragachavar A, Heimpel H, Mertelsmann R. In vivo recruitment of GM-CSF response of myelopoietic progenitor cells by interleukin-3 in aplastic anemia. Leukemia 1990; 4: 671–2
   PubMed Web of Science ®Google Scholar
• Nimer S D, Golde D W, Kwan K, Lee K, Clarke S, Champlin R. In vitro production of granulocyte-macrophage colony-stimulating factor in aplastic anemia: possible mechanism of action of antithymocyte globulin. Blood 1991; 78: 163–8
   PubMed Web of Science ®Google Scholar
• Greenberg P L. Treatment of myelodysplastic syndromes. Blood Rev 1991; 5: 42–50
   PubMed Web of Science ®Google Scholar
• Greenberg P L, Negrin R, Nagler A. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes. Cancer Surv 1990; 9: 199–212
   PubMedGoogle Scholar
• Ganser A, Janssen J W, Ottmann O G, et al. In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders. Leukemia 1991; 5: 487–92
   PubMed Web of Science ®Google Scholar
• Nagler A, Binet C, Mackichan M L, et al. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF. Blood 1990; 76: 1299–307
   PubMed Web of Science ®Google Scholar
• Estey E H, Kurzrock R, Talpaz M, et al. Effects of low doses of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 1991; 77: 291–5
   PubMed Web of Science ®Google Scholar
• Davey R T, Jr, Davey V J, Metcalf J A, et al. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 1991; 164: 43–52
   PubMed Web of Science ®Google Scholar
• Scadden D T, Bering H A, Levine J D, et al. GM-CSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment of AIDS-associated Kaposi's sarcoma. Am J Clin Oncol 1991; 14(S1)S40–4
   Google Scholar
• Scadden D T, Bering H A, Levine J D, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991; 9: 802–8
   PubMed Web of Science ®Google Scholar
• Perno C F, Cooney D A, Currens M J, et al. Ability of anti-HIV agents to inhibit HIV replication in monocyte/ macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody. AIDS Res Hum Retroviruses 1990; 6: 1051–5
   PubMed Web of Science ®Google Scholar
• Emminger W, Emminger-Schmidmeier W, Peters C, et al. Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state. Blut 1990; 61: 219–21
   PubMedGoogle Scholar
• Hartmann L C, Edmonson J H. Atrial fibrillation during treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF). Proc Am Soc Clin Oncol 1990; 9: 194
   Google Scholar
• Verhoef G, Boogaerts M. Treatment with granulocyte-macrophage colony-stimulating factor and the adult respiratory distress syndrome. Am J Haematol 1991; 36: 285–7
   PubMed Web of Science ®Google Scholar
• Bennett C L, Greenberg P, Gulati S C, Advani R, Bonnem E. GM-CSF decreases duration of cytopenia and hospitalization. and in-hospital costs in patients with Hodgkin's disease treated with high-dose chemotherapy and autologous bone-marrow transfusion (ABMT) (Abstract). Blood 1990; 76((Suppl.))
   PubMedGoogle Scholar
• Donahue R E, Seehra J, Metzger M, et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1988; 241: 1820–3
   PubMed Web of Science ®Google Scholar
• Ganser A, Lindeman A, Seipelt G, et al. Synergistic effects of sequential IL-3/GM-CSF treatment in comparison to IL-3 alone in vivo (Abstract). Blood 1990; 76((Suppl.))
   Google Scholar